Ratings by Wedbush (Martin Fan)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/9/2026 | Zura Bio Ltd. | ZURA | New Coverage | Outperform (N/A) |
6.01 (6.97) |
15.97% | Details | |
| 11/25/2025 | ImageneBio | IMA | New Coverage | Underperform (N/A) |
6.91 (5.84) |
-15.48% | Details | |
| 11/25/2025 | Vor Biopharma, Inc. | VOR | New Coverage | Neutral (N/A) |
8.36 (15.12) |
80.86% | Details | |
| 10/27/2025 | Fate Therapeutics | FATE | Upgrade | Outperform (Neutral) |
1.65 (1.33) |
-19.39% | Details | |
| 9/24/2025 | Sana Biotechnology | SANA | New Coverage | Outperform (N/A) |
3.26 (3.15) |
-3.37% | Details | |
| 7/9/2025 | Cartesian Therapeutics | RNAC | New Coverage | Outperform (N/A) |
11.30 (6.85) |
-39.38% | Details | |
| 5/28/2025 | Aclaris Therapeutis | ACRS | New Coverage | Outperform (N/A) |
1.27 (3.06) |
140.94% | Details | |
| 3/20/2025 | Zenas Biopharma | ZBIO | New Coverage | Outperform (N/A) |
8.25 (25.28) |
206.42% | Details |
